These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24599141)

  • 1. Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure.
    Hamabe L; Kawamura K; Kim SM; Yoshiyuki R; Fukayama T; Shimizu M; Fukushima R; Tanaka R
    J Pharmacol Sci; 2014; 124(3):386-93. PubMed ID: 24599141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of SCH00013: a novel Ca2+ sensitizer.
    Endoh M; Sugawara H; Mineshima M
    Cardiovasc Drug Rev; 2001; 19(4):345-66. PubMed ID: 11830752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SCH00013, a novel Ca(2+) sensitizer with positive inotropic and no chronotropic action in heart failure.
    Tadano N; Morimoto S; Yoshimura A; Miura M; Yoshioka K; Sakato M; Ohtsuki I; Miwa Y; Takahashi-Yanaga F; Sasaguri T
    J Pharmacol Sci; 2005 Jan; 97(1):53-60. PubMed ID: 15644593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 1st communication: phosphodiesterase III inhibitory effect and class III antiarrhythmic effect in guinea-pig heart.
    Hino M; Sugawara H; Yoshimura A; Ogura A; Yoshioka K; Sakato M; Endoh M
    Arzneimittelforschung; 1999 May; 49(5):398-406. PubMed ID: 10367101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 3rd communication: stereoselectivity of the enantiomers in cardiovascular effects.
    Sugawara H; Hino M; Yoshimura A; Yoshioka K; Sakato M; Endoh M
    Arzneimittelforschung; 1999 May; 49(5):412-9. PubMed ID: 10367103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
    Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium.
    Uhlmann R; Schwinger RH; Lues I; Erdmann E
    Basic Res Cardiol; 1995; 90(5):365-71. PubMed ID: 8585857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure.
    Asanoi H; Ishizaka S; Kameyama T; Ishise H; Sasayama S
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):268-74. PubMed ID: 7511757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 2nd communication: in vivo cardiovascular effects and bioavailability in dogs.
    Yoshimura A; Koide Y; Yoshioka K; Hino M; Sugawara H; Sakato M; Endoh M
    Arzneimittelforschung; 1999 May; 49(5):407-11. PubMed ID: 10367102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure.
    Pouleur H; Hanet C; Schröder E; Col J; Van Mechelen H; Etienne J; Rousseau MF
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S18-22. PubMed ID: 2478787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel cardiotonic agent SCH00013 acts as a Ca++ sensitizer with no chronotropic activity in mammalian cardiac muscle.
    Sugawara H; Endoh M
    J Pharmacol Exp Ther; 1998 Oct; 287(1):214-22. PubMed ID: 9765340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
    von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure.
    Ishiki R; Ishihara T; Izawa H; Nagata K; Hirai M; Yokota M
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):897-905. PubMed ID: 10836724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive chronotropic and inotropic effects of pimobendan (UD-CG 115 BS) in isolated, cross-circulated canine heart preparations.
    Furukawa Y; Akahane K; Ogiwara Y; Haniuda M; Chiba S
    Arch Int Pharmacodyn Ther; 1989; 300():159-73. PubMed ID: 2575887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparate force-frequency effects of pimobendan and dobutamine in conscious dogs with tachycardia-induced cardiomyopathy.
    Joho S; Asanoi H; Ishizaka S; Kameyama T; Inoue H
    J Card Fail; 2002 Dec; 8(6):423-30. PubMed ID: 12528096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic profile of the cardiotonic agent pimobendan.
    van Meel JC; Diederen W
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S1-6. PubMed ID: 2478784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Calcium sensitizer agents in heart failure therapy].
    Iwama Y; Takagi A
    Nihon Rinsho; 2007 May; 65 Suppl 5():61-5. PubMed ID: 17571366
    [No Abstract]   [Full Text] [Related]  

  • 18. Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.
    Nonaka M; Morimoto S; Murayama T; Kurebayashi N; Li L; Wang YY; Arioka M; Yoshihara T; Takahashi-Yanaga F; Sasaguri T
    Br J Pharmacol; 2015 May; 172(9):2369-82. PubMed ID: 25560565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inotropic effects of a single intravenous recommended dose of pimobendan in healthy dogs.
    Hori Y; Taira H; Nakajima Y; Ishikawa Y; Yumoto Y; Maekawa Y; Oshiro A
    J Vet Med Sci; 2019 Jan; 81(1):22-25. PubMed ID: 30404952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
    Fitton A; Brogden RN
    Drugs Aging; 1994 May; 4(5):417-41. PubMed ID: 8043944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.